PDCD1 and cancer: These strategies consist of neutralizing antibodies against negative immune checkpoints as Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), Programmed Cell Death 1 (PD-1), and PD-1 Ligand-1 (PD-L1), thereby impeding the ability of cancer cells to evade the immune surveillance program [17].